BiotechTube

Evacetrapib + Atorvastatin + Ezetimibe + Placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia

Trial Timeline

Oct 1, 2014 → Dec 1, 2015

NCT ID
NCT02227784

About Evacetrapib + Atorvastatin + Ezetimibe + Placebo

Evacetrapib + Atorvastatin + Ezetimibe + Placebo is a phase 3 stage product being developed by Eli Lilly for Hyperlipidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02227784. Target conditions include Hyperlipidemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02227784Phase 3Terminated

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
VK2809 + PlaceboViking TherapeuticsPhase 2
47
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
77
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
77
Diet+pravastatinDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
85
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
77
exenatideEli LillyPre-clinical
23
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SCEli LillyPhase 1
33
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
33
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
41
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
52
Rosuvastatin (Crestor)AstraZenecaApproved
85
simvastatin + EzetimibeMerckApproved
85
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
77
simvastatin 20 mg/ezetimibeMerckPhase 2/3
65
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
77
Sitagliptin + PlaceboMerckPhase 2/3
65
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)NovartisPhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85